目的    探讨进展期胃癌术中腹腔化疗的临床价值。方法    回顾性分析2008年1月至2011年3月期间在中山大学附属第一医院行根治性手术联合术中腹腔化疗的86例T3-4期胃癌病人临床病理资料和预后，并与同期行根治性手术未联合术中腹腔化疗的245例T3-4期胃癌病人进行比较，研究术中腹腔化疗对胃癌病人围手术期并发症、复发和预后的影响。结果    联合术中腹腔化疗组手术并发症发生率明显高于未联合腹腔化疗组（5.8% vs. 1.2%，P=0.048）。联合腹腔化疗组复发率为18.6%（16/86），对照组复发率为12.2%（30/245），两组差异无统计学意义（P=0.142）。2年的总存活率术中腹腔化疗组为64.0%，与对照组的63.4%比较差异无统计学意义（P=0.742）。Cox回归分析结果显示术中腹腔化疗并非胃癌病人的独立预后因素（HR=0.918，P=0.742）。结论    胃癌术中腹腔化疗有增加手术并发症的风险,对术后复发和预后的影响需进一步研究。

Retrospective study of intra-peritoneal chemotherapy for T3-4 gastric cancer        WEI Zhe-wei，ZHANG Chang-hua，XIA Guang-gai，et al. Department of Gastrointestinal Pancreatic Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China 
Corresponding author: ZHANG Chang-hua, E-mail: zhchangh@mail.sysu.edu.cn
Abstract    Objective    To evaluate efficacy of intra-peritoneal chemotherapy for advanced gastric cancer.  Methods Between January 2008 and March 2011, patients with T3-4 gastric cancer who were performed radical dissection only (non-IOC group, n=245) or radical dissection plus intra-peritoneal chemotherapy (IOC group, n=86) in the First Affiliated Hospital of Sun Yat-Sen University, were retrospectively enrolled in this study. Clinicopathological characteristics and survival status were compared between the two groups. Results    Postoperative complications occurred in 5.8 % patients in the IOC group which was significantly higher than that in the non-IOC group (p=0.048). Recurrence rate was 18.6% in the IOC group and 12.2% in the non-IOC group (p=0.142). Two-year overall survival in the IOC group was 64.0% which was similar to that in the non-IOC group (63.4%, p=0.742). Multivariate analysis showed that intra-peritoneal chemotherapy was not an independent prognostic factor for gastric cancer patients (HR=0.918, P=0.742). Conclusions    Intra-peritoneal chemotherapy may be related to increasing postoperative complications while its effect on recurrence and prognosis should be further investigated.